{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:00:37Z","timestamp":1794830437646,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.radonc.2011.12.029","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T17:03:56Z","timestamp":1328115836000},"page":"25-31","source":"Crossref","is-referenced-by-count":107,"title":["A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis"],"prefix":"10.1016","volume":"103","clinical-trial-number":[{"clinical-trial-number":"umin000002173","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kazuki","family":"Terashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Demizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongcun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasue","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Sirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ku","family":"Yonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Hishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2011.12.029_b0005","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.12.029_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2004.047191","article-title":"Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry","volume":"54","author":"Carpelan-Holmstrom","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.radonc.2011.12.029_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.radonc.2011.12.029_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0973-1482.42253","article-title":"Pancreatic resectional surgery: an evidence-based perspective","volume":"4","author":"D\u2019Souza","year":"2008","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.radonc.2011.12.029_b0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MPA.0b013e3181a85999","article-title":"Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer","volume":"38","author":"Galloway","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.radonc.2011.12.029_b0155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group","volume":"80","author":"GITSG","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2011.12.029_b0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijrobp.2008.04.012","article-title":"Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer","volume":"73","author":"Huang","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0040","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO;2-L","article-title":"Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy","volume":"91","author":"Ikeda","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2011.12.029_b0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jjco\/hyq011","article-title":"Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506","volume":"40","author":"Ishii","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.12.029_b0050","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.24998","article-title":"High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer","volume":"116","author":"Iwata","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2011.12.029_b0055","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0360-3016(02)02949-8","article-title":"Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center","volume":"54","author":"Kagawa","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.15675","article-title":"A phase I study of proton beam therapy for locally advanced pancreatic cancer: analysis of feasibility and anti-tumor effect","volume":"26","author":"Kamigaki","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.12.029_b0065","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","article-title":"Radiation dose\u2013volume effects in the stomach and small bowel","volume":"76","author":"Kavanagh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0070","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","article-title":"Radiation dose\u2013volume effects in the spinal cord","volume":"76","author":"Kirkpatrick","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26134","article-title":"Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma","author":"Komatsu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2011.12.029_b0080","first-page":"55","article-title":"Radiosensitization by gemcitabine","volume":"13","author":"Lawrence","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.radonc.2011.12.029_b0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0360-3016(03)00435-8","article-title":"Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study","volume":"57","author":"Li","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0090","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2011.12.029_b0095","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ijrobp.2004.01.035","article-title":"5-Fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I\u2013II dose-escalation study","volume":"59","author":"Morganti","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"Murphy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ijrobp.2006.12.071","article-title":"Proton-beam therapy for olfactory neuroblastoma","volume":"68","author":"Nishimura","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjc.6602001","article-title":"Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer","volume":"91","author":"Okusaka","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2011.12.029_b0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF02482964","article-title":"The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection","volume":"29","author":"Ozaki","year":"1999","journal-title":"Surg Today"},{"key":"10.1016\/j.radonc.2011.12.029_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4506","article-title":"Eastern Cooperative Oncology Group. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201","volume":"26","author":"Loehrer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.12.029_b0125","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2006.09.7816","article-title":"Particle radiation therapy using proton and heavier ion beams","volume":"25","author":"Schulz.-Ertner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.12.029_b0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0360-3016(01)02806-1","article-title":"Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer","volume":"53","author":"Shinchi","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.12.029_b0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.radonc.2011.12.029_b0145","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2011.12.029_b0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPA.0b013e31816d8185","article-title":"Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy","volume":"37","author":"Wong","year":"2008","journal-title":"Pancreas"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T20:44:10Z","timestamp":1713473050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814012000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0167814012000023"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2011.12.029","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}